DIADIA1.05%
SPYSPY0.23%
QQQQQQ1.14%
Trending
Top trending tickerSNDKSNDK17.62%
SKHYSKHY13.75%
QQQQQQ1.14%
MUMU11.20%
MSFTMSFT1.51%
KORUKORU30.04%
SOFISOFI0.77%
STXSTX5.20%
BEBE1.42%
SPYSPY0.23%
Top trending tickerSNDKSNDK17.62%
SKHYSKHY13.75%
QQQQQQ1.14%
MUMU11.20%
MSFTMSFT1.51%
KORUKORU30.04%
SOFISOFI0.77%
STXSTX5.20%
BEBE1.42%
SPYSPY0.23%

Feed

News

Sentiment

Earnings

Fundamentals

Info

homeSymbolAARDnews
Exchange: NASDAQ·Updated 07:34 PM EDT
AARD logo

AARDAardvark Therapeutics Inc

$6.42
$0.27
(4.04%)
Today
Closed $6.42
$0.00
(0.00%)
After Hours
EarningsAug 13
Mkt Cap$146.41M
Vol53,215.00
News
all
press releases
Aardvark Therapeutics (AARD) Scrutinized Again After FDA Hold on Lead Drug Candidate, May Announcement Drives Stock 32% Lower - Hagens Berman
Aardvark Therapeutics (AARD) Scrutinized Again After FDA Hold on Lead Drug Candidate, May Announcement Drives Stock 32% Lower - Hagens Berman Aardvark Therapeutics (AARD) Scrutinized Again After FDA Hold on Lead Drug Candidate, May Announcement Drives Stock 32% Lower - Hagens Berman PR Newswire SAN...
PR Newswire
More News
Aardvark Therapeutics (AARD) Faces Investor Scrutiny Amid 56% Drop On Clinical Pause For Lead Drug Candidate- HBSS
Aardvark Therapeutics (AARD) Faces Investor Scrutiny Amid 56% Drop On Clinical Pause For Lead Drug Candidate- HBSS Aardvark Therapeutics (AARD) Faces Investor Scrutiny Amid 56% Drop On Clinical Pause For Lead Drug Candidate- HBSS PR Newswire SAN FRANCISCO, June 19, 2026 SAN FRANCISCO, June 19, 2026...
PR Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aardvark Therapeutics, Inc. - AARD
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aardvark Therapeutics, Inc. - AARD INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aardvark Therapeutics, Inc. - AARD PR Newswire NEW YORK, June 11, 2026 NEW YORK, June 11, 2026...
PR Newswire
Aardvark Therapeutics (AARD) Faces Investor Scrutiny Amid 56% Drop On Clinical Pause For Lead Drug Candidate- HBSS
Aardvark Therapeutics (AARD) Faces Investor Scrutiny Amid 56% Drop On Clinical Pause For Lead Drug Candidate- HBSS Aardvark Therapeutics (AARD) Faces Investor Scrutiny Amid 56% Drop On Clinical Pause For Lead Drug Candidate- HBSS PR Newswire SAN FRANCISCO, May 28, 2026 SAN FRANCISCO, May 28, 2026...
PR Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aardvark Therapeutics, Inc. - AARD
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aardvark Therapeutics, Inc. - AARD INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aardvark Therapeutics, Inc. - AARD PR Newswire NEW YORK, May 21, 2026 NEW YORK, May 21, 2026...
PR Newswire
Aardvark Therapeutics (AARD) Faces Investor Scrutiny Amid 56% Drop On Clinical Pause For Lead Drug Candidate- Hagens Berman
Aardvark Therapeutics (AARD) Faces Investor Scrutiny Amid 56% Drop On Clinical Pause For Lead Drug Candidate- Hagens Berman Aardvark Therapeutics (AARD) Faces Investor Scrutiny Amid 56% Drop On...
PR Newswire
AARD Stock Crashes 34% – Here’s Why This Analyst Finds It ‘Hard To Lean Into’ Aardvark At This Stage
Following a clinical hold on its lead drug candidate, multiple brokerages downgraded and cut AARD’s price target.
Stocktwits
FDA Halts Aardvark Therapeutics Rare Disease Study
FDA places full clinical hold on Aardvark's ARD-101 studies as the company reviews Phase 3 safety and efficacy data.read more...
Benzinga
AARD Stock Plummets After Hours As Cardiac Safety Concerns Trigger FDA Hold On Late-stage Program
Aardvark Therapeutics said the FDA’s full clinical hold applies to the ongoing late-stage HERO trial for hyperphagia in PWS patients and the associated open-label extension (OLE) study.
Stocktwits
Aardvark Therapeutics (AARD) Faces Investor Scrutiny Amid 56% Drop On Clinical Pause For Lead Drug Candidate- Hagens Berman
Aardvark Therapeutics (AARD) Faces Investor Scrutiny Amid 56% Drop On Clinical Pause For Lead Drug Candidate- Hagens Berman Aardvark Therapeutics (AARD) Faces Investor Scrutiny Amid 56% Drop On...
PR Newswire
<
1
2
>

Advertisement|Remove ads.

Advertisement|Remove ads.